Sherlock Biosciences Announces Appointment of Bryan Dechairo as President and Chief Executive Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced that Bryan Dechairo, Ph.D. has been appointed president and chief executive officer. He will also join Sherlock’s board of directors. He succeeds Co-Founder Rahul Dhanda, who will continue to serve as a board member until the end of 2021 and then as strategic adviser in 2022.
“After a year of unprecedented growth and acceleration of our CRISPR and synthetic biology technologies, Sherlock is poised to disrupt diagnostics through the launch of real-world solutions that provide accurate, actionable health information wherever and whenever it is needed,” said Jim Collins, Ph.D., co-founder and board member of Sherlock Biosciences. “Bryan brings 20-plus years of experience spanning research to commercial, with a proven track record of funding and scaling business from venture-backed start-ups to profitable public companies. We feel confident that his vast experience, coupled with his passion for providing patient access to effective and cost-saving novel technologies, will lead us into the next chapter for Sherlock.”
Dr. Dechairo joins Sherlock from Myriad Genetics, where he was executive vice president of clinical development. Dr. Dechairo oversaw the development portfolio, delivering business-critical evidentiary data for value-based reimbursement and market acceptance of commercial and novel diagnostic products across six business units globally. Before joining Myriad, he was chief medical officer, chief scientific officer and senior vice president of research and development at Assurex Health, which was acquired by Myriad in 2016. Prior to Assurex Health, Dr. Dechairo held roles of increasing responsibility at Medco Health Solutions, Pfizer and other diagnostic and therapeutics companies. He also served on the board of directors for the National Alliance on Mental Illness, and educated and mentored the next generation of clinical leaders through his role as assistant professor of pharmacology at the University of Cincinnati. Dr. Dechairo has published more than 50 academic and research-based publications. He received his Ph.D. in human genetics from University College London and completed his undergraduate studies in integrative biology at University of California, Berkeley.
“I’m thrilled to be joining Sherlock at such a pivotal moment for the company,” said Dr. Dechairo. “The past year’s successes are a remarkable testament to the commitment of this team and the disruptive potential of the SHERLOCK™ and INSPECTR™ platforms. I look forward to leveraging my experience in global diagnostic product commercialization to advance Sherlock’s mission to decentralize and democratize advanced molecular diagnostics, bringing easy, rapid and accurate diagnostic tests where and when they are needed most.”
“Bryan’s depth and breadth of experience scaling businesses will enable the company to accelerate growth and development of both our SHERLOCK and INSPECTR platforms,” said Michael Rubin, M.D., Ph.D., board member of Sherlock Biosciences. “Our continued success is built on the solid foundation that Rahul and his team have put into place, and we thank him for his tremendous contributions in reaching this inflection point. We are grateful for his continued guidance and extensive knowledge of the diagnostics space, which is invaluable to our team.”
About Sherlock Biosciences
Sherlock Biosciences is dedicated to providing global access to the simplest and most accurate tests that empower individuals to control their own healthcare. Through its Engineering Biology platforms, the company is developing applications of SHERLOCK™, a CRISPR-based method for “smart amplicon detection,” and INSPECTR™, a synthetic biology-based molecular diagnostics platform that is instrument-free. SHERLOCK and INSPECTR can be used in virtually any setting without complex instrumentation, opening up a wide range of potential applications in areas including precision oncology, infection identification, food safety, at-home tests and disease detection in the field. In 2020, the company made history with the first FDA-authorized use of CRISPR technology. For more information visit Sherlock.bio.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210712005231/en/
Dan Budwick, 1AB
Source: Sherlock Biosciences
View this news release online at: